Gefitinib has the potential to alleviate lung fibrosis induced by BLM via the HMGB1/NOXs-ROS/EGFR-MAPKs-AP-1/NF-κB pathway (Li et al. 2018). The gene discussed is NFKB1; the disease is pulmonary fibrosis.